Cofactor Genomics

Cofactor Genomics
TypePrivate
IndustryBiotechnology and Bioinformatics Services
FoundedSt. Louis, Missouri, U.S. (2008 (2008))
Headquarters
San Francisco, California
,
U.S.
Area served
Worldwide
Key people
Jarret Glasscock (CEO), Jon Armstrong (CSO), David Messina (COO)
Websitewww.cofactorgenomics.com

Cofactor Genomics is a biotech company that primarily focuses on drug development, medical research, and personalized medicine.

Overview

Cofactor Genomics was founded in August 2008 by Jarret Glasscock, Matt Hickenbotham, and Ryan Richt. The technological advances brought on by Next Gen sequencing encouraged Glasscock, Hickenbotham and Richt to leave Washington University Genome Center and purchase their first Next Gen genome analyzer with capital raised from an angel investor in California.[1][2]

In November 2013, Cofactor Genomics opened a 10,000 ft2 headquarters in St. Louis, MO. The company also had offices in San Diego and San Francisco that later closed. In July 2015, Cofactor Genomics was awarded a $1.5 million Phase II Small Business Innovation Research (SBIR) grant by the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH).[3] In addition to working with clients such as Ozzy Osbourne,[4] Cofactor Genomics is involved in a number of research projects, including the preservation of the White Rhino and the Black Footed Ferret.

Executive officers

Jarret Glasscock is a co-founder as well as the chief executive officer of Cofactor Genomics.[5] Glasscock completed his undergraduate degree at the University of Arizona, where he majored in biology with a focus in the computer sciences. Upon graduation, Glasscock pursued his doctorate in genetics at Washington University in St. Louis, where he studied under Warren Gish, developer of the NCBI BLAST sequence analysis program.[5][6][7]

Jon Armstrong is the chief scientific officer of Cofactor Genomics.[5] After acquiring his master's degree in neuroscience, Armstrong spent nine years in the Genome Center at Washington University's Technology Development Group.[5]

David Messina is the chief operating officer of Cofactor Genomics. He has spent the last 19 years in computational biology and genetics. He worked on the Human Genome Project at Washington University in St. Louis, trained in molecular biology and human genetics at the University of Chicago, and earned his PhD in computational biology in Stockholm, Sweden.[citation needed]

References

  1. ^ [1] Cofactor Genomics
  2. ^ St. Louis Business Journal: St. Louis startup Cofactor to sequence Ozzy's genome [2]
  3. ^ "Cofactor Genomics Awarded $1.5M NIH Grant for Circular RNA Enrichment Tech". 21 July 2015.
  4. ^ St. Louis Business Journal: St. Louis startup Cofactor to sequence Ozzy's genome [3]
  5. ^ a b c d [4] Cofactor Genomics Contact
  6. ^ Warren Gish Warren Gish Bio
  7. ^ Lopez, R; Silventoinen, V; Robinson, S; Kibria, A; Gish, W (2003). "WU-Blast2 server at the European Bioinformatics Institute". Nucleic Acids Res. 31 (13): 3795–8. doi:10.1093/nar/gkg573. PMC 168979. PMID 12824421.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.